

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature

Date

**PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant:	Michael Joseph Coghlan	Group Art Unit:	1626
Serial No.:	10/517,010	Examiner:	S. Loewe
Application Date:	December 3, 2004	Conf No.:	1172
Title:	TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS		
Docket No.:	X-15110		

**RESPONSE TO OFFICE ACTION AND
AMENDMENT UNDER 37 C.F.R. 1.121**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Official Action dated October 12, 2007, Applicants provide arguments in response and amendments to the claims for the above-identified application:

Amendments to the specification begin on page 2.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks, including arguments in response to the pending objections and rejections, begin on page 9 of this paper.


As this response is being provided within one month of the three month shortened statutory period for response, Applicants submit that a one month extension fee is due. However, in the event any additional fees are required, the Commissioner is hereby authorized to charge Deposit Account No. 05-0840 for any such fee.

Amendments to Specification

After the claims, please insert on a separate page the following section heading and paragraph:

ABSTRACT

The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula:



Formula I

or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.